Adrian G. Sacher

9.0k total citations · 1 hit paper
153 papers, 3.1k citations indexed

About

Adrian G. Sacher is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Adrian G. Sacher has authored 153 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 99 papers in Oncology and 46 papers in Cancer Research. Recurrent topics in Adrian G. Sacher's work include Lung Cancer Treatments and Mutations (78 papers), Cancer Genomics and Diagnostics (43 papers) and Lung Cancer Research Studies (33 papers). Adrian G. Sacher is often cited by papers focused on Lung Cancer Treatments and Mutations (78 papers), Cancer Genomics and Diagnostics (43 papers) and Lung Cancer Research Studies (33 papers). Adrian G. Sacher collaborates with scholars based in Canada, United States and Australia. Adrian G. Sacher's co-authors include Geoffrey R. Oxnard, Leena Gandhi, Pasi A. Jänne, Stacy L. Mach, Suzanne E. Dahlberg, Natasha B. Leighl, Ryan S. Alden, Cloud P. Paweletz, Allison O’Connell and Lisa W. Le and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Adrian G. Sacher

136 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

2016 432 citations Adrian G. Sacher, Cloud P. Paweletz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adrian G. Sacher Canada	29	2.0k	1.7k	1.0k	809	282	153	3.1k
Caicun Zhou China	32	1.9k 1.0×	1.7k 1.0×	1.4k 1.3×	1.4k 1.7×	230 0.8×	136	3.5k
Davey B. Daniel United States	19	2.1k 1.1×	2.2k 1.3×	688 0.7×	538 0.7×	257 0.9×	82	3.3k
Hideharu Kimura Japan	26	1.5k 0.8×	1.4k 0.8×	742 0.7×	825 1.0×	226 0.8×	113	2.6k
Maria Schwaederlé United States	28	1.1k 0.6×	1.5k 0.9×	1.7k 1.6×	1.0k 1.2×	276 1.0×	43	3.2k
Ignacio Gil‐Bazo Spain	31	1.0k 0.5×	1.1k 0.7×	805 0.8×	1.2k 1.5×	169 0.6×	103	2.6k
Radek Lakomý Czechia	22	806 0.4×	1.3k 0.8×	1.0k 1.0×	1.2k 1.5×	204 0.7×	87	2.8k
David Fabrizio United States	26	1.0k 0.5×	1.9k 1.1×	927 0.9×	666 0.8×	360 1.3×	88	2.9k
Tiziana Usari Italy	17	3.5k 1.8×	3.1k 1.9×	1.0k 1.0×	1.2k 1.5×	218 0.8×	51	4.4k
Chao Zhao China	34	2.0k 1.0×	2.3k 1.4×	1.0k 1.0×	1.1k 1.4×	273 1.0×	132	3.8k
Willemijn S.M.E. Theelen Netherlands	16	3.3k 1.7×	3.0k 1.8×	873 0.8×	998 1.2×	297 1.1×	33	4.4k

Countries citing papers authored by Adrian G. Sacher

Since Specialization

Citations

This map shows the geographic impact of Adrian G. Sacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian G. Sacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian G. Sacher more than expected).

Fields of papers citing papers by Adrian G. Sacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian G. Sacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian G. Sacher. The network helps show where Adrian G. Sacher may publish in the future.

Co-authorship network of co-authors of Adrian G. Sacher

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian G. Sacher. A scholar is included among the top collaborators of Adrian G. Sacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian G. Sacher. Adrian G. Sacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Pinjiang, Nhu‐An Pham, Matthew Waas, et al.. (2025). Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. British Journal of Cancer. 134(1). 165–174.

Barua, Reeta, Mengqi Li, Di Jiang, et al.. (2024). Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study. BMJ Open. 14(3). e081480–e081480. 2 indexed citations

Skoulidis, Ferdinandos, Kristof Cuppens, Adrian G. Sacher, et al.. (2024). Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). TPS8651–TPS8651. 6 indexed citations

Lau, Sally C. M., Ben X. Wang, Susanne Penny, et al.. (2024). Circulating metabolic profiling as a biomarker for immune checkpoint blockade efficacy.. Journal of Clinical Oncology. 42(16_suppl). 2564–2564. 1 indexed citations

Dharia, Neekesh V., Tomi Jun, Julie Chang, et al.. (2024). Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Clinical Cancer Research. 30(17). 3788–3797. 9 indexed citations

Park, Cheol‐Kyu, Nhu‐An Pham, Stephanie M. Wong, et al.. (2024). Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research. JTO Clinical and Research Reports. 6(3). 100781–100781. 2 indexed citations

Sacher, Adrian G., Miguel A. Villalona‐Calero, Bert H. O’Neil, et al.. (2024). 604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors. Annals of Oncology. 35. S484–S485. 4 indexed citations

Feng, Jiao, Katrina Hueniken, Zhenzhen Fan, et al.. (2023). 1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations. Annals of Oncology. 34. S778–S778. 1 indexed citations

Anagnostou, Valsamo, Cheryl Ho, Garth Nicholas, et al.. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29(10). 2559–2569. 66 indexed citations

10.

Cheema, Parneet, Shantanu Banerji, Normand Blais, et al.. (2023). Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology. 30(7). 6473–6496. 1 indexed citations

11.

Iams, Wade T., Sharon Phillips, Adrian G. Sacher, et al.. (2023). A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer. 24(3). 228–234. 2 indexed citations

12.

Melosky, Barbara, Paul Wheatley‐Price, Rosalyn A. Juergens, et al.. (2021). The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 160. 136–151. 51 indexed citations

13.

Skoulidis, Ferdinandos, Martin Schüler, Jennifer Moriatis Wolf, et al.. (2021). MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib. Journal of Thoracic Oncology. 16(10). S929–S930. 1 indexed citations

14.

Melosky, Barbara, Parneet Cheema, Rosalyn A. Juergens, et al.. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13. 4277468338–4277468338. 4 indexed citations

15.

Li, Janice J.N., Mike Sung, Lisa W. Le, et al.. (2020). Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer. 150. 159–163. 31 indexed citations

16.

Stockley, Tracy, Ming‐Sound Tsao, Joshua C. Morganstein, et al.. (2018). P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. Journal of Thoracic Oncology. 13(10). S717–S717.

17.

Sacher, Adrian G., Kimberly M. Komatsubara, & Geoffrey R. Oxnard. (2017). Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review. Journal of Thoracic Oncology. 12(9). 1344–1356. 70 indexed citations

18.

Bahcall, Magda, Taebo Sim, Cloud P. Paweletz, et al.. (2016). Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. 6(12). 1334–1341. 114 indexed citations

19.

Paweletz, Cloud P., Adrian G. Sacher, Ryan S. Alden, et al.. (2015). Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clinical Cancer Research. 22(4). 915–922. 177 indexed citations

20.

Sacher, Adrian G., Lisa W. Le, & Natasha B. Leighl. (2014). Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping. Journal of Clinical Oncology. 32(14). 1407–1411. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact